Form D · Biotechnology

BioVaxys Technology Corp.

Etobicoke, A6 · CIK 0001882559

Offering snapshot reported Jul 12, 2024 · SEC filing

Reported sold
$52.3K
Offering amount: $173K
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 10, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 12, 2024Initial$52,324No comparison1SEC filing
Sep 22, 2021Initial$248,540No comparison8SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired, Other
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-518554
Dollar amounts have been converted from Canadian dollars using the 0.7318 Bank of Canada daily exchange rate on 5-10-24. Total Remaining to be Sold represents the aggregate exercise price of all warrants sold in the United States.
Units, each comprised of one common share and one common share purchase warrant having an exercise price of C$0.15 and a term of 24 months

Source: Form D, filed Jul 12, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
David Berd Executive
Christopher Cherry Executive
Anthony Dutton Director
Daren Hermiston Director
Kenneth Kovan Executive
Craig Loverock Director
Lachlan Mc Leod Executive
James Passin Director, Executive
David Wang Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
146 Thirtieth Street, Suite 100
Etobicoke, A6, M8W 3D4